Novo Nordisk’s Ozempic pill fails in long-shot Alzheimer’s effort

Novo shares plunged as much as 12.4% in Copenhagen, hitting the lowest level since July 2021. Their value has more than halved this year amid investor concerns over Novo’s long-term competitiveness in obesity, a booming market it helped create.

Leave a Reply

Your email address will not be published. Required fields are marked *